David J Willans

Title: The Innovations of David J Willans

Introduction

David J Willans is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of biomedical research, particularly in the development of monoclonal antibodies for cancer detection and treatment. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

David J Willans holds a patent for "Carcinoma-marking monoclonal antibodies elicited with synthetic." This patent describes monoclonal antibodies produced after immunization with a synthetic antigen that bears the structure Gal (beta 1-3) GalNac beta-glycosidically linked to a carrier moiety. These antibodies are useful as carcinoma markers. The patent also details radioimmunoimaging agents in which such antibodies are tagged with radiometals or radiohalogens. Notably, the radiolabeled monoclonal antibody 155H.7, elicited by this antigen, rapidly localizes and persists in tumor tissues, demonstrating its utility as a tumor imaging agent.

Career Highlights

David J Willans has worked at Biomira, Inc., where he has been instrumental in advancing cancer research through his innovative approaches. His work has not only contributed to the scientific community but has also provided valuable tools for clinicians in the fight against cancer.

Collaborations

Throughout his career, David has collaborated with notable colleagues, including Connie J Turner and Bryan M Longenecker. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in the field.

Conclusion

David J Willans is a distinguished inventor whose work in monoclonal antibodies has made a significant impact on cancer research. His patent and contributions to Biomira, Inc. reflect his commitment to improving medical diagnostics and treatment options. His innovative spirit continues to inspire advancements in the biomedical field.